Head of Pharmacology & Drug Dev Group & CRI Core

Research Group Home Page: 
Jodrell Group

Work address: 
Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
Publications: 

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.

E-pub date: 31 Aug 2019


Quantifying drug-induced bone marrow toxicity using a novel haematopoiesis systems pharmacology model.

E-pub date: 31 Aug 2019


Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses.

E-pub date: 31 May 2019


Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.

E-pub date: 31 Dec 2018


The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.

E-pub date: 11 Jun 2018


Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

E-pub date: 01 Jun 2018


CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

E-pub date: 01 May 2018


Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

E-pub date: 31 Mar 2018


Understanding Hematological Toxicities Using Mathematical Modeling.

E-pub date: 31 Mar 2018


A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

E-pub date: 20 Mar 2018


A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway.

E-pub date: 06 Mar 2018


Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.

E-pub date: 31 Jan 2018


New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.

E-pub date: 20 Aug 2017


Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.

E-pub date: 01 Jul 2017


Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.

E-pub date: 31 May 2017


A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level.

E-pub date: 15 Jan 2017


mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

E-pub date: 01 Dec 2016


Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

E-pub date: 08 Nov 2016


Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

E-pub date: 01 Oct 2016


Combenefit: an interactive platform for the analysis and visualization of drug combinations.

E-pub date: 15 Sep 2016


Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.

E-pub date: 31 Jul 2016


Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability.

E-pub date: 21 Jun 2016


An automated fitting procedure and software for dose-response curves with multiphasic features.

E-pub date: 01 Oct 2015


GEMMs as preclinical models for testing pancreatic cancer therapies.

E-pub date: 01 Oct 2015


CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

E-pub date: 01 Sep 2015


The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data.

E-pub date: 01 Feb 2015


Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.

E-pub date: 31 Jan 2015


The EGFR demonstrates linear signal transmission.

E-pub date: 31 Aug 2014


Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

E-pub date: 15 Jul 2014


SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

E-pub date: 01 Jun 2014


Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

E-pub date: 10 Dec 2013


Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes.

E-pub date: 21 Nov 2013


Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.

E-pub date: 31 Aug 2013


CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

E-pub date: 23 Jul 2013


Adaptive designs for dual-agent phase I dose-escalation studies.

E-pub date: 31 May 2013


γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).

E-pub date: 01 Feb 2013


Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

E-pub date: 31 Jan 2013


Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.

E-pub date: 31 Oct 2012


Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD.

E-pub date: 30 Oct 2012


Progress in pancreatic cancer: moving beyond gemcitabine?

E-pub date: 31 Aug 2012


Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

E-pub date: 31 Aug 2012


A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer.

E-pub date: 15 Aug 2012


Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

E-pub date: 27 May 2012


nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

E-pub date: 31 Mar 2012


Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.

E-pub date: 12 Mar 2012


Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

E-pub date: 31 Jan 2012


A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

E-pub date: 01 Nov 2011


Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

E-pub date: 31 Jul 2011


Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

E-pub date: 18 Jun 2011


A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.

E-pub date: 01 Apr 2011


Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters.

E-pub date: 31 Dec 2010


Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

E-pub date: 01 Oct 2010


Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme.

E-pub date: 31 Jul 2010


Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents.

E-pub date: 08 Apr 2010


How many cisplatin administration protocols does your department use?

E-pub date: 01 Jan 2010


Capecitabine (oral 5-fluorouracil pro-drug) treatment for colorectal carcinoma causing ischaemic chest pain.

E-pub date: 31 Aug 2009


Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro.

E-pub date: 31 Jul 2009


Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

E-pub date: 01 Jun 2009


Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

E-pub date: 01 Apr 2009


Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.

E-pub date: 15 Mar 2009


ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136.

E-pub date: 31 Aug 2008


A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.

E-pub date: 31 Jul 2008


Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

E-pub date: 15 May 2008


Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.

E-pub date: 15 Feb 2008


The impact of prognosis without treatment on doctors’ and patients’ resource allocation decisions and its relevance to new drug recommendation processes.

E-pub date: 01 Feb 2008


Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.

E-pub date: 31 Jan 2008


Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

E-pub date: 01 Nov 2007


Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model.

E-pub date: 31 Oct 2007


Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

E-pub date: 01 Aug 2007


Developing and piloting a nurse-led model of follow-up in the multidisciplinary management of colorectal cancer.

E-pub date: 31 Jul 2007


Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer.

E-pub date: 31 May 2007


Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.

E-pub date: 31 Dec 2003


Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

E-pub date: 01 Dec 2003


Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.

E-pub date: 31 Oct 2002


Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

E-pub date: 31 Jan 2002


Inhibition of cancer cell growth by ruthenium(II) arene complexes.

E-pub date: 30 Sep 2001


A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

E-pub date: 01 Dec 2000


Formula-based dosing for carboplatin.

E-pub date: 01 Sep 1999


Development of a gradient elution high-performance liquid chromatography assay with ultraviolet detection for the determination in plasma of the anticancer peptide [Arg6, D-Trp7,9, mePhe8]-substance P (6-11) (antagonist G), its major metabolites and a C-terminal pyrene-labelled conjugate.

E-pub date: 31 Aug 1999


A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

E-pub date: 01 Dec 1998


Population pharmacokinetics of gentamicin in patients with cancer.

E-pub date: 01 Sep 1998


Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

E-pub date: 01 May 1998


Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.

E-pub date: 01 Mar 1998


Effects of nitric oxide manipulation on the disposition of platinum in an experimental glioma model.

E-pub date: 31 Dec 1997


Antimicrobial practice. Development of guidelines for gentamicin dosing.

E-pub date: 01 Nov 1996


Retroperitoneal surgery: its wider role in the management of malignant teratoma.

E-pub date: 01 Apr 1996


Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.

E-pub date: 01 Jun 1995


Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

E-pub date: 01 Oct 1994


A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.

E-pub date: 01 Aug 1994


The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice.

E-pub date: 30 Nov 1993


Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agents.

E-pub date: 01 Aug 1993


Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.

E-pub date: 01 Aug 1993


Suramin, an active drug for prostate cancer: interim observations in a phase I trial.

E-pub date: 31 Mar 1993


The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.

E-pub date: 01 Nov 1991


The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).

E-pub date: 30 Sep 1991


ICI D1694, an inhibitor of thymidylate synthase for clinical study.

E-pub date: 01 Aug 1991


The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats.

E-pub date: 01 Aug 1991


A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

E-pub date: 01 May 1991


Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2′-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscopy.

E-pub date: 01 Nov 1990


Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study.

E-pub date: 01 Aug 1990


The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.

E-pub date: 01 Nov 1988


Myelosuppression after methotrexate, mitoxantrone, and mitomycin C.

E-pub date: 30 Apr 1987


Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate.

E-pub date: 28 Feb 1987


Show all
Research Integrity Conflict of Interest Disclosure: 
Last revised: 
05/11/2018
Company Active Research funding Ownership Royalty payments Commitment to carry out work for a fee Ad hoc reimbursed work Travel Gifts/ other
Astex No No No No Yes No No No
Bicycle Therapeutics No Yes No No No No No No
BTG No No No Yes No No No No
AstraZeneca Yes Yes No No No No No No
Boehringer Ingelheim Yes Yes No No No No No No
GSK Yes Yes No No No No No No
Roche Yes Yes No No No No No No
Sanofi Yes Yes No No No No No Yes
Shionogi Yes Yes No No No No No No
Disclosure guidelines